Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors...
Gespeichert in:
| Veröffentlicht in: | Frontiers in Pharmacology 2016-07, Vol.7 (197) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 197 |
| container_start_page | |
| container_title | Frontiers in Pharmacology |
| container_volume | 7 |
| creator | de Bruijn, Winnie Ibáñez, Cristina Frisk, Pia Bak Pedersen, Hanne Alkan, Ali Vella Bonanno, Patricia Brkičić, Ljiljana S Bucsics, Anna Dedet, Guillaume Eriksen, Jaran Fadare, Joseph O Fürst, Jurij Gallego, Gisselle Godói, Isabella P Guerra Júnior, Augusto A Gürsöz, Hakkı Jones, Jan Joppi, Roberta Kerman, Saim Laius, Ott Madzikwa, Newman Magnússon, Einar Maticic, Mojca Markovic-Pekovic, Vanda Massele, Amos Ogunleye, Olayinka O'Leary, Aisling Piessnegger, Jutta Sermet, Catherine Simoens, Steven Tiroyakgosi, Celda Truter, Ilse Thyberg, Magnus Tomekova, Kristina Wladysiuk, Magdalena Vandoros, Sotiris Vural, Elif H Zara, Corinne Godman, Brian |
| description | Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens. |
| format | Article |
| fullrecord | <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_548143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_548143</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_5481433</originalsourceid><addsrcrecordid>eNqNjD0LwjAYhIMoWNT_8G4OUrBNrS2OorSD4KCuJSRvNVqTkg8Rf71SHBy95e6Bu-uRIEpTGuZZFPd_8pBMrL3OP6J5TtMkIKJUzmjhuZNaAVMCjk428sU61jUU8nyBvZEcBRTrE-xQSC4VWmDcaGth441ucQXlvW0k73YWam3AXRC23nmDYzKoWWNx8vURmW43h3UR3nyD_oGqErZlHKsopskiXWZ5tUiyKKF0RGb_NSv3dPT_3zcWqVZp</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future</title><source>Lirias (KU Leuven Association)</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>de Bruijn, Winnie ; Ibáñez, Cristina ; Frisk, Pia ; Bak Pedersen, Hanne ; Alkan, Ali ; Vella Bonanno, Patricia ; Brkičić, Ljiljana S ; Bucsics, Anna ; Dedet, Guillaume ; Eriksen, Jaran ; Fadare, Joseph O ; Fürst, Jurij ; Gallego, Gisselle ; Godói, Isabella P ; Guerra Júnior, Augusto A ; Gürsöz, Hakkı ; Jones, Jan ; Joppi, Roberta ; Kerman, Saim ; Laius, Ott ; Madzikwa, Newman ; Magnússon, Einar ; Maticic, Mojca ; Markovic-Pekovic, Vanda ; Massele, Amos ; Ogunleye, Olayinka ; O'Leary, Aisling ; Piessnegger, Jutta ; Sermet, Catherine ; Simoens, Steven ; Tiroyakgosi, Celda ; Truter, Ilse ; Thyberg, Magnus ; Tomekova, Kristina ; Wladysiuk, Magdalena ; Vandoros, Sotiris ; Vural, Elif H ; Zara, Corinne ; Godman, Brian</creator><creatorcontrib>de Bruijn, Winnie ; Ibáñez, Cristina ; Frisk, Pia ; Bak Pedersen, Hanne ; Alkan, Ali ; Vella Bonanno, Patricia ; Brkičić, Ljiljana S ; Bucsics, Anna ; Dedet, Guillaume ; Eriksen, Jaran ; Fadare, Joseph O ; Fürst, Jurij ; Gallego, Gisselle ; Godói, Isabella P ; Guerra Júnior, Augusto A ; Gürsöz, Hakkı ; Jones, Jan ; Joppi, Roberta ; Kerman, Saim ; Laius, Ott ; Madzikwa, Newman ; Magnússon, Einar ; Maticic, Mojca ; Markovic-Pekovic, Vanda ; Massele, Amos ; Ogunleye, Olayinka ; O'Leary, Aisling ; Piessnegger, Jutta ; Sermet, Catherine ; Simoens, Steven ; Tiroyakgosi, Celda ; Truter, Ilse ; Thyberg, Magnus ; Tomekova, Kristina ; Wladysiuk, Magdalena ; Vandoros, Sotiris ; Vural, Elif H ; Zara, Corinne ; Godman, Brian</creatorcontrib><description>Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><ispartof>Frontiers in Pharmacology, 2016-07, Vol.7 (197)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,776,780,27837</link.rule.ids></links><search><creatorcontrib>de Bruijn, Winnie</creatorcontrib><creatorcontrib>Ibáñez, Cristina</creatorcontrib><creatorcontrib>Frisk, Pia</creatorcontrib><creatorcontrib>Bak Pedersen, Hanne</creatorcontrib><creatorcontrib>Alkan, Ali</creatorcontrib><creatorcontrib>Vella Bonanno, Patricia</creatorcontrib><creatorcontrib>Brkičić, Ljiljana S</creatorcontrib><creatorcontrib>Bucsics, Anna</creatorcontrib><creatorcontrib>Dedet, Guillaume</creatorcontrib><creatorcontrib>Eriksen, Jaran</creatorcontrib><creatorcontrib>Fadare, Joseph O</creatorcontrib><creatorcontrib>Fürst, Jurij</creatorcontrib><creatorcontrib>Gallego, Gisselle</creatorcontrib><creatorcontrib>Godói, Isabella P</creatorcontrib><creatorcontrib>Guerra Júnior, Augusto A</creatorcontrib><creatorcontrib>Gürsöz, Hakkı</creatorcontrib><creatorcontrib>Jones, Jan</creatorcontrib><creatorcontrib>Joppi, Roberta</creatorcontrib><creatorcontrib>Kerman, Saim</creatorcontrib><creatorcontrib>Laius, Ott</creatorcontrib><creatorcontrib>Madzikwa, Newman</creatorcontrib><creatorcontrib>Magnússon, Einar</creatorcontrib><creatorcontrib>Maticic, Mojca</creatorcontrib><creatorcontrib>Markovic-Pekovic, Vanda</creatorcontrib><creatorcontrib>Massele, Amos</creatorcontrib><creatorcontrib>Ogunleye, Olayinka</creatorcontrib><creatorcontrib>O'Leary, Aisling</creatorcontrib><creatorcontrib>Piessnegger, Jutta</creatorcontrib><creatorcontrib>Sermet, Catherine</creatorcontrib><creatorcontrib>Simoens, Steven</creatorcontrib><creatorcontrib>Tiroyakgosi, Celda</creatorcontrib><creatorcontrib>Truter, Ilse</creatorcontrib><creatorcontrib>Thyberg, Magnus</creatorcontrib><creatorcontrib>Tomekova, Kristina</creatorcontrib><creatorcontrib>Wladysiuk, Magdalena</creatorcontrib><creatorcontrib>Vandoros, Sotiris</creatorcontrib><creatorcontrib>Vural, Elif H</creatorcontrib><creatorcontrib>Zara, Corinne</creatorcontrib><creatorcontrib>Godman, Brian</creatorcontrib><title>Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future</title><title>Frontiers in Pharmacology</title><description>Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens.</description><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqNjD0LwjAYhIMoWNT_8G4OUrBNrS2OorSD4KCuJSRvNVqTkg8Rf71SHBy95e6Bu-uRIEpTGuZZFPd_8pBMrL3OP6J5TtMkIKJUzmjhuZNaAVMCjk428sU61jUU8nyBvZEcBRTrE-xQSC4VWmDcaGth441ucQXlvW0k73YWam3AXRC23nmDYzKoWWNx8vURmW43h3UR3nyD_oGqErZlHKsopskiXWZ5tUiyKKF0RGb_NSv3dPT_3zcWqVZp</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>de Bruijn, Winnie</creator><creator>Ibáñez, Cristina</creator><creator>Frisk, Pia</creator><creator>Bak Pedersen, Hanne</creator><creator>Alkan, Ali</creator><creator>Vella Bonanno, Patricia</creator><creator>Brkičić, Ljiljana S</creator><creator>Bucsics, Anna</creator><creator>Dedet, Guillaume</creator><creator>Eriksen, Jaran</creator><creator>Fadare, Joseph O</creator><creator>Fürst, Jurij</creator><creator>Gallego, Gisselle</creator><creator>Godói, Isabella P</creator><creator>Guerra Júnior, Augusto A</creator><creator>Gürsöz, Hakkı</creator><creator>Jones, Jan</creator><creator>Joppi, Roberta</creator><creator>Kerman, Saim</creator><creator>Laius, Ott</creator><creator>Madzikwa, Newman</creator><creator>Magnússon, Einar</creator><creator>Maticic, Mojca</creator><creator>Markovic-Pekovic, Vanda</creator><creator>Massele, Amos</creator><creator>Ogunleye, Olayinka</creator><creator>O'Leary, Aisling</creator><creator>Piessnegger, Jutta</creator><creator>Sermet, Catherine</creator><creator>Simoens, Steven</creator><creator>Tiroyakgosi, Celda</creator><creator>Truter, Ilse</creator><creator>Thyberg, Magnus</creator><creator>Tomekova, Kristina</creator><creator>Wladysiuk, Magdalena</creator><creator>Vandoros, Sotiris</creator><creator>Vural, Elif H</creator><creator>Zara, Corinne</creator><creator>Godman, Brian</creator><general>Frontiers Media S.A</general><scope>FZOIL</scope></search><sort><creationdate>201607</creationdate><title>Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future</title><author>de Bruijn, Winnie ; Ibáñez, Cristina ; Frisk, Pia ; Bak Pedersen, Hanne ; Alkan, Ali ; Vella Bonanno, Patricia ; Brkičić, Ljiljana S ; Bucsics, Anna ; Dedet, Guillaume ; Eriksen, Jaran ; Fadare, Joseph O ; Fürst, Jurij ; Gallego, Gisselle ; Godói, Isabella P ; Guerra Júnior, Augusto A ; Gürsöz, Hakkı ; Jones, Jan ; Joppi, Roberta ; Kerman, Saim ; Laius, Ott ; Madzikwa, Newman ; Magnússon, Einar ; Maticic, Mojca ; Markovic-Pekovic, Vanda ; Massele, Amos ; Ogunleye, Olayinka ; O'Leary, Aisling ; Piessnegger, Jutta ; Sermet, Catherine ; Simoens, Steven ; Tiroyakgosi, Celda ; Truter, Ilse ; Thyberg, Magnus ; Tomekova, Kristina ; Wladysiuk, Magdalena ; Vandoros, Sotiris ; Vural, Elif H ; Zara, Corinne ; Godman, Brian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_5481433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Bruijn, Winnie</creatorcontrib><creatorcontrib>Ibáñez, Cristina</creatorcontrib><creatorcontrib>Frisk, Pia</creatorcontrib><creatorcontrib>Bak Pedersen, Hanne</creatorcontrib><creatorcontrib>Alkan, Ali</creatorcontrib><creatorcontrib>Vella Bonanno, Patricia</creatorcontrib><creatorcontrib>Brkičić, Ljiljana S</creatorcontrib><creatorcontrib>Bucsics, Anna</creatorcontrib><creatorcontrib>Dedet, Guillaume</creatorcontrib><creatorcontrib>Eriksen, Jaran</creatorcontrib><creatorcontrib>Fadare, Joseph O</creatorcontrib><creatorcontrib>Fürst, Jurij</creatorcontrib><creatorcontrib>Gallego, Gisselle</creatorcontrib><creatorcontrib>Godói, Isabella P</creatorcontrib><creatorcontrib>Guerra Júnior, Augusto A</creatorcontrib><creatorcontrib>Gürsöz, Hakkı</creatorcontrib><creatorcontrib>Jones, Jan</creatorcontrib><creatorcontrib>Joppi, Roberta</creatorcontrib><creatorcontrib>Kerman, Saim</creatorcontrib><creatorcontrib>Laius, Ott</creatorcontrib><creatorcontrib>Madzikwa, Newman</creatorcontrib><creatorcontrib>Magnússon, Einar</creatorcontrib><creatorcontrib>Maticic, Mojca</creatorcontrib><creatorcontrib>Markovic-Pekovic, Vanda</creatorcontrib><creatorcontrib>Massele, Amos</creatorcontrib><creatorcontrib>Ogunleye, Olayinka</creatorcontrib><creatorcontrib>O'Leary, Aisling</creatorcontrib><creatorcontrib>Piessnegger, Jutta</creatorcontrib><creatorcontrib>Sermet, Catherine</creatorcontrib><creatorcontrib>Simoens, Steven</creatorcontrib><creatorcontrib>Tiroyakgosi, Celda</creatorcontrib><creatorcontrib>Truter, Ilse</creatorcontrib><creatorcontrib>Thyberg, Magnus</creatorcontrib><creatorcontrib>Tomekova, Kristina</creatorcontrib><creatorcontrib>Wladysiuk, Magdalena</creatorcontrib><creatorcontrib>Vandoros, Sotiris</creatorcontrib><creatorcontrib>Vural, Elif H</creatorcontrib><creatorcontrib>Zara, Corinne</creatorcontrib><creatorcontrib>Godman, Brian</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>Frontiers in Pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Bruijn, Winnie</au><au>Ibáñez, Cristina</au><au>Frisk, Pia</au><au>Bak Pedersen, Hanne</au><au>Alkan, Ali</au><au>Vella Bonanno, Patricia</au><au>Brkičić, Ljiljana S</au><au>Bucsics, Anna</au><au>Dedet, Guillaume</au><au>Eriksen, Jaran</au><au>Fadare, Joseph O</au><au>Fürst, Jurij</au><au>Gallego, Gisselle</au><au>Godói, Isabella P</au><au>Guerra Júnior, Augusto A</au><au>Gürsöz, Hakkı</au><au>Jones, Jan</au><au>Joppi, Roberta</au><au>Kerman, Saim</au><au>Laius, Ott</au><au>Madzikwa, Newman</au><au>Magnússon, Einar</au><au>Maticic, Mojca</au><au>Markovic-Pekovic, Vanda</au><au>Massele, Amos</au><au>Ogunleye, Olayinka</au><au>O'Leary, Aisling</au><au>Piessnegger, Jutta</au><au>Sermet, Catherine</au><au>Simoens, Steven</au><au>Tiroyakgosi, Celda</au><au>Truter, Ilse</au><au>Thyberg, Magnus</au><au>Tomekova, Kristina</au><au>Wladysiuk, Magdalena</au><au>Vandoros, Sotiris</au><au>Vural, Elif H</au><au>Zara, Corinne</au><au>Godman, Brian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future</atitle><jtitle>Frontiers in Pharmacology</jtitle><date>2016-07</date><risdate>2016</risdate><volume>7</volume><issue>197</issue><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens.</abstract><pub>Frontiers Media S.A</pub><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1663-9812 |
| ispartof | Frontiers in Pharmacology, 2016-07, Vol.7 (197) |
| issn | 1663-9812 1663-9812 |
| language | eng |
| recordid | cdi_kuleuven_dspace_123456789_548143 |
| source | Lirias (KU Leuven Association); DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| title | Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T23%3A38%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Introduction%20and%20Utilization%20of%20High%20Priced%20HCV%20Medicines%20across%20Europe;%20Implications%20for%20the%20Future&rft.jtitle=Frontiers%20in%20Pharmacology&rft.au=de%20Bruijn,%20Winnie&rft.date=2016-07&rft.volume=7&rft.issue=197&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_548143%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |